BRCA Mutations Treatment Market - Regional Analysis
North American Market Insights
North America industry is set to account for largest revenue share of 39% by 2035. This growth will be noticed owing to the increasing advancement in technology for the treatment of cancer in this region. There have been significant investments made by the public and commercial sectors. According to the National Library of Medicine, with expenditures topping USD 4.7 billion, or about 20% of the whole NIH budget, the National Cancer Institute (NCI) is now the biggest institution supported by the National Institute on Health (NIH).
The U.S. will hold a good position in the BRCA mutations treatment market because of the rising advancement in healthcare infrastructure. The United States' healthcare system was placed sixth in the world in the 2021 World Index on Healthcare Innovation, which was compiled by the Foundation for Research on Equal Opportunity (FREOPP).
The Canadian BRCA mutation treatment sector will increase rapidly because of the increasing chronic disease in this country. In 2021, 45.1% of Canadians had at least one serious chronic illness.
APAC Market Insights
The BRCA mutations treatment market in the APAC region will also encounter huge growth during the estimated timeframe and will hold the second position owing to the increasing frequency of ovarian cancer in this region. One of the most prevalent diseases in women is ovarian cancer, which is frequently detected as an advanced stage due to the early signs of the disease's modest symptoms. Over 39,000 people lost their lives to OC in the APAC region in 2020, while over 57,000 new cases were recorded.
In China, the industry will increase because of the rising government initiatives to cure cancer. The National Cancer Center (NCC) of China estimates that 4,064,000 newly diagnosed cases of cancer were recorded.
South Korea will also notice a huge expansion because of the unique advent of chemotherapies in this country. With almost 2 million cancer survivors in Korea recently, the Korean Cancer Society projected that up to 260,000 Koreans may receive a new cancer diagnosis in 2021.
The Japanese BRCA mutations treatment market will rise because of the rising number of geriatric patients in this country. As per the National Institute of Population and Social Security Research, by 2040, the proportion of the Japanese population aged 65 and above is predicted to be 34.8%. The home healthcare services have also increased in demand.
